The hypermethylation of ERBB receptor feedback inhibitor 1 (ERRFI1), paired-like homeodomain transcription factor 2 (PITX2) and downstream of kinase 7 (DOK7) promoters avoid PI3K/AKT/mTOR pathway inhibition conferring chemotherapy resistance to breast cancer. This evidence concerns the gene AKT1 and breast carcinoma.